Pfizer has launched its 20-valent pneumococcal conjugate vaccine (PCV20) in India, offering single-dose protection against 20 ...

Indian equity benchmarks closed lower in a volatile Tuesday session, weighed down by blue-chip bank stocks and caution ahead ...

Indian equity markets opened on a cautious note, a day after recording a sharp recovery that snapped a six-week losing streak ...

Pfizer's share price gained today after the company announced the launch of its next-generation 20-valent pneumococcal ...

Indian benchmarks indices, the BSE Sensex and NSE Nifty, are set to open in positive terrain on Tuesday, taking firm cues ...

Stocks like Highway Infrastructure, Hindalco Industries, Pfizer, Medi Assist, Adani Enterprises, and HG Infra Engineering ...

Single-dose PCV20 approved for adults 18 years and older, covering 20 pneumococcal serotypes, including both invasive and non ...

PCV20 will be available as a single-shot vaccine and those vaccinated with PCV20 may not need a second dose, the drug maker ...

Pfizer has introduced its 20-valent pneumococcal conjugate vaccine, PCV20, in India to provide protection against 20 serotypes of pneumococcal disease. The single-shot vaccine is aimed at adults, ...